Wells Fargo analyst David Maris upgraded Teva Pharmaceutical to Market Perform from Underperform and raised his price target for the shares to $23 from $18. The analyst had a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. Claims by investors that the new CEO is exactly what Teva needs seem to be well-founded, Maris tells investors in a research note. He thinks the "stage seems to be well set for a good narrative in the near-term." Maris also believes that consensus earnings estimates for Teva are too low. As such, the analyst does not see the stock underperforming in the near-term. Maris, however, maintains his caution on the longer-term generic industry margin risks.